Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer

Urology. 2004 Apr;63(4):742-5. doi: 10.1016/j.urology.2003.10.063.

Abstract

Objectives: To assess the effects of androgen deprivation therapy on body composition in men with nonmetastatic prostate cancer.

Methods: In a multicenter study, men with Stage M0 prostate cancer were prospectively evaluated during initial androgen deprivation therapy (gonadotropin-releasing hormone agonist or bilateral orchiectomy). The main outcomes were changes in weight, percentage fat mass, and percentage lean mass from baseline to 12 months.

Results: Seventy-nine subjects were assessed. Serum testosterone concentrations decreased by 79.7% +/- 3.0% (P <0.001). Weight increased by 1.8% +/- 0.5% (P <0.001). The percentage fat mass increased by 11.0% +/- 1.7%, and the percentage lean mass decreased by 3.8% +/- 0.6% (P <0.001 for each comparison).

Conclusions: Androgen deprivation therapy increased weight and fat mass and decreased lean mass in men with nonmetastatic prostate cancer.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / drug effects
  • Adult
  • Aged
  • Androgen Antagonists / pharmacology
  • Androgen Antagonists / therapeutic use*
  • Body Composition / drug effects
  • Body Composition / physiology*
  • Body Mass Index
  • Body Weight / drug effects
  • Body Weight / physiology*
  • Flutamide / therapeutic use
  • Gonadotropin-Releasing Hormone / agonists
  • Gonadotropin-Releasing Hormone / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Orchiectomy*
  • Prospective Studies
  • Prostate / pathology
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery
  • Prostatic Neoplasms / therapy*
  • Testosterone / antagonists & inhibitors
  • Testosterone / blood

Substances

  • Androgen Antagonists
  • Gonadotropin-Releasing Hormone
  • Testosterone
  • Flutamide